Specific binding of an antigen-antibody complex to apoptotic human neutrophils by Hart, Simon P et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific binding of an antigen-antibody complex to apoptotic
human neutrophils
Citation for published version:
Hart, SP, Jackson, C, Kremmel, LM, McNeill, MS, Jersmann, H, Alexander, KM, Ross, JA & Dransfield, I
2003, 'Specific binding of an antigen-antibody complex to apoptotic human neutrophils' American Journal Of
Pathology, vol 162, no. 3, pp. 1011-8. DOI: 10.1016/S0002-9440(10)63895-3
Digital Object Identifier (DOI):
10.1016/S0002-9440(10)63895-3
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
American Journal Of Pathology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Specific Binding of an Antigen-Antibody Complex to
Apoptotic Human Neutrophils
Simon P. Hart,* Caroline Jackson,*
L. Maximillian Kremmel,* Mary S. McNeill,*
Hubertus Jersmann,* Karen M. Alexander,*
James A. Ross,† and Ian Dransfield*
From the Medical Research Council Centre for Inflammation
Research,* University of Edinburgh Medical School, Edinburgh;
and the Edinburgh University Department of Surgery,† Royal
Infirmary, Edinburgh, Scotland
Examination of apoptotic cell surface molecules has so
far failed to reveal cell type-specific membrane alter-
ations that serve as a signal for phagocytosis. In the
present study we have identified a novel murine mono-
clonal antibody, BOB93, which bound to the surface of
apoptotic neutrophils but not to apoptotic lympho-
cytes. BOB93 binding to apoptotic neutrophils was de-
pendent on the presence of the sialoglycoprotein fe-
tuin, a constituent of bovine serum. We demonstrate
that fetuin is the antigen for BOB93, and that BOB93 and
fetuin form a complex in solution that is necessary and
sufficient for binding to apoptotic neutrophils. Individ-
uals who were homozygous for an adenine nucleotide
at position 519 of the gene for the immune complex
receptor FcRIIA exhibited markedly reduced binding
of BOB93/fetuin. This report is the first to provide evi-
dence that antigen-antibody complexes bind specifi-
cally to apoptotic neutrophils and implicates apoptosis-
associated changes in Fc receptor function. (Am J
Pathol 2003, 162:1011–1018)
Neutrophils have been implicated in the pathogenesis of
a variety of inflammatory diseases including the adult
respiratory distress syndrome, idiopathic pulmonary fi-
brosis, ulcerative colitis, and rheumatoid arthritis.1 Al-
though the neutrophil is a vital component of the body’s
defense against infectious agents, uncontrolled release
of its formidable array of toxic substances may inflict
“friendly fire” damage on surrounding tissue and propa-
gate the inflammatory response, leading to scarring and
tissue destruction.2 The fate of recruited neutrophils,
which are present in large numbers at a site of inflamma-
tion, is apoptosis3 culminating in recognition and safe
disposal of the dying cells by phagocytes.4,5 Neutrophil
apoptosis is associated with down-regulation of poten-
tially harmful cellular functions, such as stimulated re-
lease of granule contents,6,7 and leads to surface mem-
brane alterations that signal noninflammatory phagocytic
clearance by macrophages.
Efficient removal of apoptotic cells before release of their
potentially harmful intracellular contents is critical because if
excessive apoptotic cell load occurs, development of auto-
immune or chronic inflammatory pathology may ensue.8,9
The sheer diversity of surface molecules that have been
proposed to be involved in phagocyte recognition of apo-
ptotic cells implies that phagocyte recognition signals are
complex and unlikely to depend on a single molecule.5 The
molecular alterations on the surface of apoptotic cells that
are responsible for phagocyte recognition also remain to be
fully characterized. Many studies have implicated exposure
of the anionic phospholipid phosphatidylserine on the apo-
ptotic cell membrane as an important determinant of
phagocyte recognition.10–12 We and others have previously
shown that a number of alterations in the protein and car-
bohydrate composition of the plasma membrane are asso-
ciated with apoptosis.7,13–16 It has also become apparent
that apoptosis is associated with membrane alterations that
confer specific binding of plasma proteins, with the poten-
tial for opsonization and regulation of subsequent phago-
cyte recognition. In particular, there is evidence that the
collectin family of molecules, including complement com-
ponent C1q,17 mannose binding lectin,18 and surfactant
protein A,19 exhibit specific binding to apoptotic cells. How-
ever, the binding of complement components may be a
relatively late event in the apoptotic process or may even
reflect the presence of necrotic cells.20 Recently, IgM was
shown to bind to cell surface lysophospholipids on apopto-
tic Jurkat cells via its Fab portions, providing a mechanism
for complement binding to apoptotic cells.21 Other pro-
teins that may bind to apoptotic cells include the acute
phase proteins pentraxin-3,22 serum amyloid P,23 and
C-reactive protein.24 However, our data demonstrating
augmentation of phagocytosis of apoptotic neutrophils,
but not lymphocytes, after ligation of macrophage CD44
indicates that surface determinants of subsequent
phagocytic clearance may be specific to certain cell
lineages. We have therefore undertaken further studies to
characterize changes in the surface expression of car-
bohydrates and proteins associated with neutrophil
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apoptosis using dual-color flow cytometric analy-
sis.15,16 We now report the binding characteristics of a
unique monoclonal antibody, termed BOB93, which
displayed specific binding to apoptotic neutrophils.
Materials and Methods
Antibodies and Other Reagents
Cell culture materials and fetal calf serum (FCS) were
from Invitrogen (Paisley, UK) and Percoll was from Phar-
macia (Little Chalfont, UK). Monoclonal antibody (mAb)
BOB93 (IgG1 isotype) was prepared by fusion of spleno-
cytes from a BALB/c mouse immunized with the human
myelomonocytic cell line THP-1 (obtained from the
ECACC, Porton Down, UK) with Sp2/0-Ag14 (ECACC)
nonsecreting myeloma cell line. Fusion products secret-
ing immunoglobulin (Ig) were tested in flow cytometry for
reactivity with apoptotic neutrophils and subcloned twice
before further analysis. 3G8 mAb (anti-CD16) was the gift
of Dr. J. Unkeless, Mount Sinai Medical School, New
York, NY. Fluorescein isothiocyanate (FITC)-conjugated
3G8 was prepared as described previously15 and used
at a final concentration of 2 g/ml. Control mAb hybrid-
oma MOPC21C (IgG1) was obtained from the ECACC
and grown in Dulbecco’s modified Eagle’s medium plus
10% FCS. Fetuin, asialofetuin, and bovine serum albumin
were from Sigma (Poole, UK). 2-HS glycoprotein and
1-acid glycoprotein were from Calbiochem (CN Bio-
sciences, Nottingham, UK). Complexes of murine IgG1
were formed by combining 500 g/ml of biotinylated
albumin (Sigma) with 85 g/ml of FITC-conjugated anti-
biotin IgG1 (clone BN-34, Sigma) in phosphate-buffered
saline (PBS) for 30 minutes on ice, and then diluted in
PBS before use in neutrophil-binding assays.
Protein Labeling
Fetuin was dissolved at 2.5 mg/ml in PBS and dialyzed
against 100 mmol/L of sodium bicarbonate, pH 8.2. FITC
(Sigma) was dissolved at 1.5 mg/ml in dimethyl sulfoxide
and added dropwise to a total volume of 45 l per ml of
protein solution. The mixture was then incubated for 2
hours at room temperature in the dark. The FITC-protein
solution was finally gel filtered on a PD-10 column (Phar-
macia) that had been equilibrated with PBS.
Cell Isolation
Leukocytes were isolated from human peripheral blood
by dextran sedimentation and discontinuous Percoll gra-
dient centrifugation as described.25 Neutrophils were
cultured at 4  106/ml in Iscove’s modification of Dulbec-
co’s modified Eagle’s medium containing 10% autolo-
gous serum at 37°C in a 95% air/5% CO2 atmosphere for
20 hours, during which time a proportion of the cells
underwent apoptosis.3 Lymphocytes were isolated by
adherence and negative selection from the mononuclear
cell band, and apoptosis was induced by 20-hour culture
in RPMI 1640 in the absence of serum.
Flow Cytometry
Indirect immunofluorescence was used to assess anti-
body binding to leukocytes using FITC-conjugated
F(ab)2 goat anti-mouse Ig (DAKO, Ely, UK), and flow
cytometric analysis was performed as previously de-
scribed.7,15 FITC-fetuin was incubated with cells in PBS
for 30 minutes before washing. Counterstaining with an-
nexin V-PE (Caltag, Towchester, UK) was used to identify
apoptotic cells within the aged neutrophil population. All
neutrophil populations were routinely tested for exclusion
of propidium iodide and were 99% propidium iodide-
negative.
Dot Blotting
Two hundred-l samples containing proteins at 1.25
g/ml or 1:80 dilutions of serum in PBS were applied to a
nitrocellulose membrane using a dot-blot manifold. The
membrane was blocked with PBS/0.1% Tween 20 and
then incubated with 1:100 BOB93 serum-free superna-
tant for 30 minutes at room temperature. After washing
the membrane was incubated with 1:4000 goat anti-
mouse Ig-horseradish peroxidase (DAKO) and devel-
oped with enhanced chemiluminescence (Amersham,
Little Chalfont, UK).
Sodium Dodecyl Sulfate-Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and Western
Blotting
BOB93 in serum-free supernatant was ultracentrifuged at
300,000  g in a Beckman Optima TLX ultracentrifuge to
remove immunoglobulin aggregates. The supernatant
was then mixed with fetuin or bovine serum albumin
(control) at a final concentration of 0.5 mg/ml for 30
minutes on ice, before ultracentrifugation at 300,000  g
for 30 minutes. The supernatant was collected and the
pellet was washed once in PBS and resolubilized. Ali-
quots of supernatants and pellets were run on a dena-
turing 9% polyacrylamide gel, electroblotted onto
nitrocellulose, probed with 1:4000 horseradish peroxi-
dase-labeled anti-mouse Ig (DAKO), and visualized by
enhanced chemiluminescence (Amersham).
FcRIIA Genotyping
Genomic DNA was extracted from freshly isolated neu-
trophils by lysis in 0.1% SDS, 10 mmol/L Tris-HCl, pH 8,
and 1 mmol/L ethylenediaminetetraacetic acid, followed
by incubation with 100 g/ml of RNase (Sigma) for 60
minutes at 37°C. Proteins were precipitated with potas-
sium acetate and DNA was precipitated from the super-
natant in isopropanol and then ethanol. A 449-bp frag-
ment containing the polymorphism at position 519 in exon
4 of the FcRIIA gene was amplified by polymerase chain
reaction using a 50-l reaction mixture containing 20
pmol of forward primer 5-TGA GAC TGA AAA ACC CTT
GG-3; 20 pmol of reverse primer 5-CAC TCC TCT TTG
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CTC CAG TG-3; 1.5 mmol/L of MgCl2; 2.5 U of TaqDNA
polymerase (Promega) in buffer A (Promega); 200 mol/L
each of dNTPs (Promega, Southampton, UK); and 1 l of
DNA. The following cycling conditions were used: 35
cycles each comprising 30-second segments of 94°C for
30 seconds, 56°C for 30 seconds, and 72°C for 30 sec-
onds, followed by a 5-minute final extension at 72°C.
Ten-l of each product was run on a 1% agarose gel
containing ethidium bromide and photographed under
UV illumination to confirm successful amplification. Each
Figure 1. Monoclonal antibody BOB93 binds to apoptotic neutrophils. A: Apoptosis was induced in human peripheral blood neutrophils and lymphocytes during
in vitro culture. Cells were labeled with BOB93 hybridoma supernatant followed by F(ab)2 FITC-labeled goat anti-mouse Ig antibody, and analyzed by flow
cytometry (shaded histogram, control IgG1 antibody; open histogram, BOB93). Approximately 50% of cells in each population were apoptotic as assessed
by annexin V binding. B: BOB93 in hybridoma supernatant bound selectively to CD16low apoptotic cells within a population of aged neutrophils. Dual-
immunofluorescence analysis was performed using BOB93, PE-conjugated F(ab)2 anti-mouse Ig, and FITC-conjugated CD16 mAb 3G8. FL1 (y axis) represents
CD16 expression and FL2 (x axis) represents BOB93 binding. There was a time-dependent increase in neutrophil apoptosis during in vitro culture and BOB93
bound selectively to the apoptotic cells. Data are from a single experiment representative of three that were performed.
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product was then purified using a Qiagen polymerase
chain reaction purification kit and sequenced by MWG-
Biotech (Milton Keynes, UK).
Results
Antibody BOB93 Binds Specifically to Apoptotic
Neutrophils
A large number of antibodies were screened for their
binding properties to apoptotic neutrophils using dual-
color indirect immunofluorescence and flow cytometric
analysis.7,15,16 We identified one mAb cell culture super-
natant, BOB93, that bound specifically to a subpopula-
tion of neutrophils that had been cultured in vitro (Figure
1A), but exhibited very low levels of binding to freshly
isolated neutrophils. BOB93-positive neutrophils bound
annexin V, confirming that BOB93-labeled cells repre-
sented apoptotic neutrophils. To determine whether
BOB93 binding reflected a neutrophil-specific membrane
alteration associated with apoptosis we also examined
human peripheral blood lymphocytes that had been in-
duced to undergo apoptosis during serum-free culture. In
contrast with neutrophils, apoptotic lymphocytes exhib-
ited only a single BOB93low population (Figure 1A). Tem-
poral analysis revealed that binding of BOB93 to neutro-
phils closely mirrored CD16 shedding (Figure 1B),
indicating a tight association between expression of the
BOB93 binding site and other surface molecular alter-
ations associated with apoptosis. Thus, binding of
BOB93 defines a neutrophil-specific surface molecular
alteration that accompanies apoptosis.
BOB93 Binding Is Dependent on a Component
of Bovine Serum
The specific binding of BOB93 to apoptotic neutrophils
led us to further characterize the nature of the antigen
recognized by the BOB93 mAb. Initial screening was
performed using antibodies in hybridoma supernatant
that contains growth medium and 10% FCS. However, in
experiments using serum-free BOB93 hybridoma super-
natant we did not observe binding of BOB93 to apoptotic
neutrophils, despite the presence of similar levels of an-
tibody. Reconstitution of serum-free BOB93 supernatant
with 10% FCS fully restored binding to apoptotic neutro-
phils (Figure 2).
Because BOB93 failed to bind apoptotic neutrophils in
the absence of serum but FCS was able to restore cellular
reactivity, we proposed that a component of FCS was
required for antibody binding to apoptotic neutrophils.
We therefore tested whether BOB93 was able to bind to
proteins present in FCS. Dot-blot analysis confirmed that
BOB93 bound to FCS and to fetuin, one of its principal
protein constituents (Figure 3). Although fetuin displays
significant sequence homology between the many differ-
ent species in which it has been identified,26 BOB93 did
not bind to rabbit or human serum or to the human fetuin
homolog 2-HS glycoprotein. Furthermore, we did not
observe binding of BOB93 to asialofetuin, suggesting
that sialic acid-containing oligosaccharides present on
bovine fetuin are an important determinant of antibody
binding. However, sialylation does not universally confer
this property because BOB93 failed to bind the highly
sialylated 1-acid glycoprotein or to sialylated bovine
serum albumin (Figure 3 and data not shown). We have
been unable to further identify the epitope recognized by
BOB93 because unfolding of fetuin in SDS or digestion of
fetuin with trypsin both resulted in loss of antigenicity and
BOB93 did not bind to oligosaccharides prepared from
fetuin with sufficient affinity to allow further characteriza-
tion of potential epitopes (data not shown). Together our
data suggested that BOB93 recognizes fetuin in a sialic
acid-dependent and species-specific manner.
Fetuin Is Required for BOB93 Binding
Like FCS (Figure 2), fetuin restored binding of serum-free
BOB93 to apoptotic neutrophils (Figure 4A), whereas
control proteins albumin or asialofetuin had no effect
(data not shown). Peak binding of BOB93 was observed
in the presence of0.3 mg/ml of fetuin, which is similar to
its concentration in 10% FCS and thus in hybridoma
culture supernatant.27
A possible explanation for these findings was that fe-
tuin was able to bind to the apoptotic cell surface, which
consequently conferred BOB93 binding. We performed
preincubation and co-incubation experiments to directly
test this hypothesis. Aged neutrophils that had been in-
cubated with 0.3 mg/ml of fetuin and then washed did not
exhibit BOB93 binding, whereas co-incubation of 0.3
mg/ml of fetuin with BOB93 permitted binding of the
antibody (Figure 4B, top). This result suggested that fe-
tuin alone could not bind to apoptotic neutrophils. For
confirmation we performed binding studies with fetuin
Figure 2. Bob93 binding requires a constituent of bovine serum. BOB93 in
serum-free medium was incubated with aged neutrophils in the presence or
absence of 10% FCS. The cells were washed and BOB93 binding was
detected by anti-mouse Ig-FITC. In the absence of serum BOB93 did not bind
aged neutrophils. Binding was reconstituted by addition of 10% fetal calf
serum. A representative flow cytometry histogram is shown.
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that had been conjugated with FITC. FITC-labeled fetuin
did not bind to aged neutrophils, but co-incubation with
unlabeled BOB93 resulted in FITC-fetuin binding to apo-
ptotic neutrophils (Figure 4B, bottom). These results
demonstrated conclusively that fetuin alone is unable to
bind to neutrophils, but that a combination of fetuin and
BOB93 was required to bind to the apoptotic neutrophil
surface.
BOB93 and Fetuin Form a Complex in Solution
Because both BOB93 antibody and fetuin were neces-
sary for either to bind to apoptotic neutrophils, we rea-
soned that an antigen-antibody complex was formed in
solution that permitted cell binding. To test this hypothe-
sis, BOB93 and fetuin were mixed and then ultracentri-
fuged at 300,000  g to pellet any complexes that had
been formed. The presence of BOB93 antibody in the
resulting pellet or supernatant was detected by SDS-
PAGE and Western blotting using a peroxidase-labeled
anti-mouse Ig probe. Figure 5 demonstrates that after
incubation with fetuin the majority of BOB93 is present in
the ultracentrifuged pellet with very little remaining in the
supernatant, implying that a complex is indeed formed
between BOB93 and fetuin. We tested the supernatants
before and after ultracentrifugation for their ability to bind
to apoptotic neutrophils. Whereas the BOB93/fetuin start-
ing material was able to bind apoptotic neutrophils, the
postcentrifugation supernatant exhibited markedly re-
duced cell binding (Figure 5). Our interpretation of this
Figure 3. Fetuin is the BOB93 antigen. A: Proteins (1 g total protein) were
applied to nitrocellulose and allowed to dry. The membrane was blocked
with PBS/0.1% Tween 20 and then probed with BOB93 followed by goat
anti-mouse Ig-horseradish peroxidase. The membrane was developed using
enhanced chemiluminescence (Amersham). BOB93 bound specifically to
FCS and fetuin. B: Specific binding of BOB93 to fetuin was demonstrated
using serial dilutions of fetuin and asialofetuin applied to nitrocellulose,
probed, and developed as above.
Figure 4. Binding of serum-free BOB93 is reconstituted by fetuin. A: Serum-
free BOB93 was incubated with aged human neutrophils in the presence of
increasing concentrations of fetuin and binding was assessed by flow cytom-
etry. The mean fluorescence of the BOB93high apoptotic population was
recorded. In this representative experiment the mean relative fluorescence of
cells in the presence of control antibody was 4.0. B: Aged human neutrophils
were preincubated with fetuin (i) or PBS (ii), washed twice, and then
incubated with BOB93 alone (i) or BOB93 fetuin 0.3 mg/ml (ii). Detection
was with anti-mouse Ig-FITC. BOB93 did not bind to cells that were prein-
cubated with fetuin, but co-incubation with fetuin permitted binding to
apoptotic neutrophils. Bottom: FITC-labeled fetuin (0.3 mg/ml) was incu-
bated with aged neutrophils in the presence of control antibody (iii) or
BOB93 (iv). FITC-fetuin bound to apoptotic neutrophils only in the presence
of BOB93. Dot plots are shown from a representative experiment using
annexin V-PE to label apoptotic neutrophils.
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result is that a complex of BOB93 and fetuin is necessary
and sufficient to bind to apoptotic neutrophils.
Biotinylated Albumin-Anti-Biotin Complexes
Bind to Apoptotic Neutrophils
To demonstrate that binding of an antigen-antibody com-
plex to apoptotic neutrophils was not specific for BOB93/
fetuin, we used biotinylated albumin as a multivalent an-
tigen and mixed it with FITC-conjugated anti-biotin
murine IgG1 to generate labeled antigen-antibody com-
plexes in vitro. When aged human neutrophils were incu-
bated with these complexes, we observed a pattern of
preferential binding to apoptotic neutrophils that was very
similar to that seen with BOB93/fetuin (Figure 6).
BOB93/Fetuin Binding Is Determined by a
Common Polymorphism in FcRIIA
During the course of these studies we obtained repro-
ducible results using cells from more than 50 healthy
volunteer blood donors. However, we identified a small
number of individuals whose apoptotic neutrophils re-
peatedly failed to bind BOB93/fetuin. Because our data
suggested that a complex of BOB93 antibody and its
antigen, fetuin, was required for cell binding, we won-
dered whether these negative donors were equivalent to
the low-responder individuals previously identified in
studies of binding of complexed murine IgG1 to viable
human leukocytes.28 This phenomenon has been shown
to be because of a common polymorphism in the immune
complex receptor FcRIIA.29,30 We extracted genomic
DNA from neutrophils from a subset of our blood donors
and amplified the DNA sequence containing the FcRIIA
polymorphism using polymerase chain reaction. The
polymerase chain reaction product was then sequenced,
and the sequence compared with BOB93/fetuin-binding
data. These experiments confirmed that our negative
donors did indeed exhibit the low-responder genotype,
having an adenine (A) nucleotide at position 519 of the
FcRIIA gene, which leads to substitution of an arginine
residue by a histidine in the second Ig-like domain of the
receptor. All of our other donors had a guanine (G) or G/A
(Figure 7), and apoptotic neutrophils from G/G homozy-
Figure 5. Fetuin and BOB93 form a complex in solution. Serum-free BOB93
hybridoma supernatant was ultracentrifuged at 300,000  g to remove im-
munoglobulin aggregates. The supernatant was then mixed with fetuin or
bovine serum albumin (control) at a final concentration of 0.3 mg/ml for 30
minutes on ice before ultracentrifugation for 30 minutes. The supernatant
was collected and the pellet was washed once in PBS and resolubilized.
Aliquots of supernatants (S) and pellets (P) were analyzed by SDS-PAGE and
Western blotting with horseradish peroxidase-labeled anti-mouse Ig, and
visualized by enhanced chemiluminescence. After incubation with fetuin, the
majority of BOB93 antibody is detected in the pellet, with little remaining in
the supernatant. Aliquots of BOB93 alone and BOB93 plus fetuin before and
after ultracentrifugation were then tested for binding to apoptotic neutrophils
using anti-mouse Ig-FITC as a second layer. The supernatant after ultracen-
trifugation exhibited significantly diminished BOB93 binding to apoptotic
neutrophils compared with the starting material.
Figure 6. Apoptotic neutrophils bind complexes of biotinylated albumin and
anti-biotin IgG1. Aged human neutrophils were incubated with complexes of
biotinylated bovine albumin (20 g/ml) and FITC-labeled anti-biotin murine
IgG1, co-labeled with annexin V-PE, and analyzed by flow cytometry.
Figure 7. BOB93-negative donors have the low-responder polymorphism in
FcRIIA (CD32). Dot plots showing BOB93/fetuin binding to aged neutro-
phils from three different donors (top) are presented along with correspond-
ing sequencing chromatograms showing a common polymorphism in
FcRIIA (bottom). BOB93-negative donors (right) were homozygous for an
adenine (A) nucleotide at position 519 of the FcRIIA gene.
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gotes and G/A heterozygotes bound BOB93/fetuin to a
similar extent.
Discussion
With the exception of phosphatidylserine exposure, sig-
nificant positive surface changes on the apoptotic cell
surface that might determine recognition by phagocytes
have only recently been reported. Binding of blood con-
stituents such as complement components and acute-
phase proteins to apoptotic cells may allow opsonization
that will confer recognition by phagocyte receptors (eg,
C1qR, CR3, and so forth). In vivo it is likely that the
inflammatory milieu will be populated with numerous sub-
stances that could potentially opsonize apoptotic cells, in
contrast to many in vitro models of phagocytosis of apo-
ptotic cells that have used a basic serum-free environ-
ment (to allow the roles of different receptors to be ex-
amined). In the present study we have identified a novel
monoclonal antibody, BOB93, which in the hybridoma
supernatant binds specifically to apoptotic neutrophils,
but not to the apoptotic lymphocytes. The antigen recog-
nized by BOB93 was identified as fetuin, a sialylated
bovine glycoprotein that is abundantly present in fetal
serum.31 Further characterization revealed that the
BOB93 antibody alone failed to bind the apoptotic neu-
trophil surface, but that binding was dependent on the
formation of a complex between BOB93 and fetuin.
An important clue to the molecular mechanism of
BOB93/fetuin binding to apoptotic neutrophils arose from
our observation of occasional negative donors whose
cells reproducibly failed to bind BOB93/fetuin. Because a
complex between a murine antibody and its antigen was
responsible for cell binding, we hypothesized that our
negative donors may be equivalent to the low-responder
individuals in studies of complexed murine IgG1 binding
to leukocytes. Genotyping the FcRIIA polymorphism of a
number of our volunteers confirmed that the negative
donors possessed the low-responder genotype, being
homozygous for an A nucleotide at position 519 of the
gene. All of the positive donors that we genotyped were
either G/G homozygotes or G/A heterozygotes. The
genotyping result is important however because it impli-
cates neutrophil Fc receptors in the binding of antigen-
antibody complexes to apoptotic neutrophils. The periph-
eral blood lymphocytes used in the present study did not
exhibit significant expression of any Fc receptors (data
not shown). Neutrophils, however, express two receptors
for complexed IgG, FcRIIA (CD32) and FcRIIIB
(CD16), but do not express significant amounts of the
high-affinity receptor FcRI (CD64) under resting condi-
tions.32 It is well documented that during apoptosis neu-
trophils lose the majority of their FcRIIIB molecules,15
and FcRIIA expression is also significantly reduced on
apoptotic neutrophils.16 We were therefore surprised that
our data pointed to a role for Fc receptors in the binding
of BOB93/fetuin complexes to apoptotic neutrophils. In
particular, we observed little binding of BOB93/fetuin
to nonapoptotic neutrophils, implying that there may be
apoptosis-associated changes in Fc receptor function.
Clearly this observation requires further investigation, but
the novel findings reported here have several important
implications for the removal of apoptotic neutrophils from
inflammatory sites, and thus for disease pathogenesis.
Although the process of phagocyte clearance of apopto-
tic cells has been extensively studied under serum-free
conditions in vitro, the presence of serum components
including IgG may significantly influence the way in which
phagocytes recognize apoptotic cells. It has been shown
that apoptotic cell clearance fails to stimulate release of
proinflammatory mediators by macrophages in vitro.33,34
In many inflammatory diseases antigen-antibody com-
plexes may be found in the bloodstream or in the tissues
(eg, in the joint in rheumatoid arthritis) where they con-
tribute to the inflammatory process by activating Fc re-
ceptor-bearing leukocytes. Our data raise the intriguing
possibility that antigen-antibody complexes may specifi-
cally opsonize apoptotic neutrophils and consequently
modulate the mechanism by which they are recognized
and phagocytosed by macrophages.
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